Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can prostate-specific antigen nadir predict prostate cancer outcomes following radiotherapy?

Nature Clinical Practice Oncology volume 3, pages 534–535 (2006)Cite this article

boxed-textRay ME et al. (2006) PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 64: 1140–1150

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. American Society for Therapeutic Radiology and Oncology Consensus Panel (1997) Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37: 1035–1041

  2. Roach M III et al. (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65: 965–974

    Article  Google Scholar 

  3. Critz FA (2002) A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. J Urol 167: 1310–1313

    Article  Google Scholar 

  4. Lee WR (2005) What variables predict for metastasis in men with biochemical relapse following radiotherapy for prostate cancer? Nat Clin Pract Oncol 2: 340–341

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Sandra Ford, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology,

    W Robert Lee & Judd W Moul

  2. Division of Urology, Duke University School of Medicine, Durham, NC, USA

    W Robert Lee & Judd W Moul

Authors
  1. W Robert Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Judd W Moul
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W Robert Lee.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, W., Moul, J. Can prostate-specific antigen nadir predict prostate cancer outcomes following radiotherapy?. Nat Rev Clin Oncol 3, 534–535 (2006). https://doi.org/10.1038/ncponc0612

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0612

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing